Recent advances and discoveries in the mechanisms and functions of CAR T cells
This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …
[HTML][HTML] The journey of CAR-T therapy in hematological malignancies
J Lu, G Jiang - Molecular cancer, 2022 - Springer
Chimeric antigen receptor T (CAR-T) cells therapy has revolutionized the treatment
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
paradigms for hematological malignancies, with multi-line therapy-refractory patients …
[HTML][HTML] Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy
Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …
[HTML][HTML] Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL
J Zhang, Y Hu, J Yang, W Li, M Zhang, Q Wang… - Nature, 2022 - nature.com
Recently, chimeric antigen receptor (CAR)-T cell therapy has shown great promise in
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
treating haematological malignancies,,,,,–. However, CAR-T cell therapy currently has …
[PDF][PDF] Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the …
OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …
[HTML][HTML] Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
Mechanisms of resistance to CAR T cell therapy
NN Shah, TJ Fry - Nature reviews Clinical oncology, 2019 - nature.com
The successes with chimeric antigen receptor (CAR) T cell therapy in early clinical trials
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
involving patients with pre-B cell acute lymphoblastic leukaemia (ALL) or B cell lymphomas …
[HTML][HTML] CAR T cell therapy for solid tumors: bright future or dark reality?
J Wagner, E Wickman, C DeRenzo, S Gottschalk - Molecular therapy, 2020 - cell.com
Chimeric antigen receptor (CAR) T cell therapy has garnered significant excitement due to
its success for hematological malignancies in clinical studies leading to the US Food and …
its success for hematological malignancies in clinical studies leading to the US Food and …
[HTML][HTML] CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments
Chimeric antigen receptor (CAR)-T cell therapy is a progressive new pillar in immune cell
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
therapy for cancer. It has yielded remarkable clinical responses in patients with B-cell …
[HTML][HTML] Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
SS Neelapu, S Tummala, P Kebriaei… - Nature reviews Clinical …, 2018 - nature.com
Immunotherapy using T cells genetically engineered to express a chimeric antigen receptor
(CAR) is rapidly emerging as a promising new treatment for haematological and non …
(CAR) is rapidly emerging as a promising new treatment for haematological and non …